DoD Gulf War Illness New Investigator Award

The summary for the DoD Gulf War Illness New Investigator Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Gulf War Illness New Investigator Award: The New Investigator Award (NIA) mechanism is being offered by the GWIRP for the first time in FY14. The intent of the GWIRP NIA is to support investigators new to the field of GWI research at different stages of career development. This award enables such investigators to compete for funding separately from investigators with established programs of GWI research. Previous experience in GWI research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in GWI research are strongly encouraged to strengthen their applications through collaboration with investigators who are experienced in GWI research and/or possess other relevant expertise. It is the PI’s responsibility to describe how the collaboration(s) will augment his or her ability to address the research question. DoD FY14 GWIRP New Investigator Award 4 All applicants for the NIA must meet specific eligibility criteria under one of the following categories, as described in Section I.C., Eligibility Information. • Transitioning Postdoctoral Fellow • Early-Career Investigator • New GWI Researcher The NIA is designed to promote new ideas in GWI research and establish proof-of-principle for further development in future studies. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on sound scientific rationale and may reflect clinical observations or seek to evaluate discoveries made in relation to other chronic multi-symptom illnesses for their application in GWI. Regardless of the approach, the focus should be clearly on veterans with GWI. It is the responsibility of the PI to clearly and explicitly articulate the project’s potential impact on GWI. The NIA supports research focusing on the complex of symptoms known as GWI, improving the case definition and diagnosis of GWI, characterizing disease symptoms, and better understanding the pathobiology. The NIA encourages basic through clinical research aimed at identification of objective measures (e.g., biomarkers) to distinguish healthy veterans from those with GWI, or improve understanding of the pathobiology underlying symptoms associated with GWI. Particular topic areas of interest include biological processes or abnormalities in GWI associated with: • Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology • Central neuroinflammatory processes • Autonomic nervous system function • Neuroendocrine measures • Immune parameters/Indicators of chronic infection • Gastrointestinal complaints/symptoms • Genetic, genomic, proteomic, or metabolic characteristics • Respiratory symptoms • Sexual dysfunction • Sleep problems Applications may also address other topic areas that are directly relevant to GWI. Studies that characterize chronic effects of neurotoxic exposures at dosages comparable to that encountered in-theatre during the Gulf War are of interest. Studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. All studies using animal models should use an established model unless there is a compelling scientific justification for the development or use of a new model. Development of new animal models is discouraged. The NIA can also be used for testing of GWI-targeted pharmacologic agents in Adsorption, Distribution, Metabolism, Excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C. et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.nc3rs.org.uk/page.asp?id=1357.
Federal Grant Title: DoD Gulf War Illness New Investigator Award
Federal Agency Name: Dept of the Army USAMRAA
Grant Categories: Science and Technology
Type of Opportunity: Discretionary
Funding Opportunity Number: W81XWH-14-GWIRP-NIA
Type of Funding: Cooperative Agreement, Grant
CFDA Numbers: 12.420
CFDA Descriptions: Military Medical Research and Development
Current Application Deadline: Sep 25, 2014
Original Application Deadline: Sep 25, 2014
Posted Date: May 7, 2014
Creation Date: May 7, 2014
Archive Date: Oct 25, 2014
Total Program Funding: $1,500,000
Maximum Federal Grant Award: $0
Minimum Federal Grant Award: $0
Expected Number of Awards: 2
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
CDMRP Help Desk 301-682-5507
CDMRP Help Desk

Dept. of the Army -- USAMRAA 301-619-7144
Similar Government Grants
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research a...
DoD Kidney Cancer, Clinical Consortium Award
DOD Toxic Exposures, Translational Research Award
DOD Toxic Exposures, Investigator-Initiated Research Award
DOD Toxic Exposures, Clinical Trial Award
FY2006 Deployed War Fighter Protection Research Program
Department of Defense (DOD) Fiscal Year 2003 (FY03) Breast Cancer Research Program (BCRP)C...
Department of Defense (DOD) Fiscal Year 2004 (FY04) Breast Cancer Research Program (BCRP) ...
More Grants from the Dept of the Army USAMRAA
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research a...
DoD Kidney Cancer, Clinical Consortium Award
DOD Toxic Exposures, Translational Research Award

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com